Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer

Urology

Volumn 51, Issue 1, 1998, Pages 150-157

  Alexander, Richard B ^a   Brady, Francine ^b   Leffell, Mary Sue ^b   Tsai, Van ^b   Celis, Esteban ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA A2 ANTIGEN; PEPTIDE; PROSTATE SPECIFIC ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MOLECULAR RECOGNITION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SEROTYPING; T LYMPHOCYTE;

ANTIGEN-ANTIBODY REACTIONS; CELLS, CULTURED; EPITOPES; HLA-A2 ANTIGEN; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 0031891159     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00480-9     Document Type: Article

References (32)

1. Rosenberg SA, Spiess PJ, and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233: 1318-1321, 1985.
2. Barth RJ, Bock SN, Mule JJ, and Rosenberg SA: Unique murine tumor associated antigens identified by tumor infiltrating lymphocytes. J Immunol 144: 1531-1537, 1990.
3. Muul LM, Spiess PJ, Director EP, and Rosenberg SA: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138: 989-995, 1987.
4. Topalian SL, Solomon D, and Rosenberg SA: Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714-3725, 1989.
5. Horn SS, Topalian SL, Simonis T, Mancini M, and Rosenberg SA: Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother 10: 153-164, 1991.
6. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
7. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie PG, and Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanoma. J Exp Med 178: 489-495, 1993.
8. Gaugler B, Eynde VE, Bruggen PV, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, and Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179: 921-930, 1994.
9. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow LT, Shabanowitz J, Engelhard V, Hunt DF, and Slingluff CLJ: Identification of peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719, 1994.
10. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, and Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recog-nized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91: 3515-3519, 1994.
11. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, and Boon T: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180: 35-42, 1994.
12. Robbins PF, el-Gamil M, Li YE, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, and Rosenberg SA: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 154: 5944-5950, 1995.
13. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, and Rosenberg SA: Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91: 9461-9465, 1994.
14. Houghton AN: Cancer antigens: immune recognition of self and altered self. J Exp Med 180: 1-4, 1994.
15. Epstein JI: PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North Am 20: 757-770, 1993.
16. Ruppert J, Sidney J, Cells E, Kubo RT, Grey HM, and Sette A: Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74: 929-937, 1993.
17. Bednarek MA, Sauma SY, Gammon MC, Porter G, Tamhankar S, Williamson AR, and Zweerink HJ: The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol 147: 4047-4053, 1991.
18. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, and Rosenberg SA: Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 154: 2257-2265, 1995.
19. Alexander RB, and Rosenberg SA: Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice. J Immunol 145: 1615-1620, 1990.
20. Alexander RB, Fitzgerald EB, Mixon A, Carter CS, Jakobsen M, Cohen PA, and Rosenberg SA: Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes. J Immunother 17: 39-46, 1995.
21. Kim TY, Von Eschenbach AC, Filaccio MLD, Hayakawa K, Parkinson DR, Balch CM, and Itoh K: Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma. Cancer Res 50: 5263-5268, 1990.
22. Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, Pontes E, and Bukowski R: Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50: 2363-2370, 1990.
23. Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, and Bukowski R: Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 11: 1-11, 1992.
24. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hoffstetter A, Riethmuller G, and Segurado OG: Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 151: 4209-4220, 1993.
25. Christinck ER, Luscher MA, Barber BH, and Williams DB: Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352: 67-70, 1991.
26. Koenig S, Fuerst TR, Wood LV, Woods RM, Suzich JA, Jones GM, De La Cruz VF, Davey RT Jr, Venkatesan S, and Moss B: Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. J Immunol 145: 127-135, 1990.
27. Cells E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chestnut RW, Grey HM, Sette A, and Serra HM: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91: 2105-2109, 1994.
28. Marincola FM, Rivoltini L, Salgaller ML, Player T, and Rosenberg SA: Differential anti-MART-l/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in compar-ison to healthy donors: Evidence of in vivo priming by tumor cells. J Immunother 19: 266-277, 1996.
29. Xue BH, Zhang Y, Sosman JA, and Peace DJ: Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 30: 73-78, 1997.
30. Alexander RB: Letter to the Editor. Prostate 32: 73, 1997.
31. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu MZ, Schlom J, and Tsang KY: In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89: 293-300, 1997.
32. Hawke S, Matsuo H, Nicolle M, Malcherek G, Melms A, and Willcox N: Autoimmune T cells in myasthenia gravis: Heterogeneity and potential for specific immunotargeting. Immunol Today 17: 307-311, 1996. AQ1 - are these two different affiliations Should "and" be inserted?